Thus, centrally-targeted AT1 and βAR receptor modulating pharmaceuticals in combination with physical exercise early in HF progression may combat ventilatory overdrive and mitigate respiratory muscle myopathy to improve HF symptomatology, exercise tolerance, and potentially severity classification. This evidence concerns the gene AGTR1 and hydrops fetalis.